T-cell progenitor function during progressive human immunodeficiency virus-1 infection and after antiretroviral therapyCLARK, D. R; REPPING, S; MIEDEMA, F et al.Blood. 2000, Vol 96, Num 1, pp 242-249, issn 0006-4971Article

Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) studyREIJERS, M. H. E; WEVERLING, G. J; SCHUITEMAKER, H et al.Lancet (British edition). 1998, Vol 352, Num 9123, pp 185-190, issn 0140-6736Article

Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infectionVAN DER VALK, M; GISOLF, E. H; REISS, P et al.AIDS (London). 2001, Vol 15, Num 7, pp 847-855, issn 0269-9370Article

Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapyPAKKER, N. G; KROON, E. D. M. B; KOOPMANS, P. P et al.AIDS (London). 1999, Vol 13, Num 2, pp 203-212, issn 0269-9370Article

Outcome and predictors of failure of highly active antiretroviral therapy : One-year follow-up of a cohort of human immunodeficiency virus type 1-infected personsWIT, F. W. N. M; VAN LEEUWEN, R; DE WOLF, F et al.The Journal of infectious diseases. 1999, Vol 179, Num 4, pp 790-798, issn 0022-1899Article

The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapyHOETELMANS, R. M. W; REIJERS, M. H. E; SCHUITEMAKER, H et al.AIDS (London). 1998, Vol 12, Num 11, pp F111-F115, issn 0269-9370Article